EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc
Articles
The New Pharmacovigilance Era
When purchasing a new kitchen appliance or trying a new skincare product most of us instinctively take small safety steps checking reviews looking for quality certifications or doing a quick patch test These everyday habits reflect a simple principle we rarely trust something new without validating its safety Pharmacovigilance and Safety Testing operate on that same principle but at a far larger...
Research Insights
Baseline Characteristics of SARS-CoV-2 Vaccine Non-responders in a Large Population-based Sample
Individuals with certain malignancies organ transplant recipients and immunecompromised individuals could mount either an incomplete or suboptimal antibody response to primary series vaccination
Case Studies
Quality Management In Clinical Trials: An Observational Case Study By Pfizer
Abstract Clinical trials are conducted to collect the data necessary to provide information for academia industry and regulators to make decisions about the safety and efficacy of the disease illness or preventative medicines under study To ensure investigators are following the protocol complying with regulatory and G
Techno Trends
Generative Adversarial Autoencoders to Revolutionize New Medications
An international group of computer scientists have developed a Generative Adversarial Autoencoders AAE for generating novel molecular finger prints with a defined set of parameters A layer AAE architecture with the latent middle layer serving as a discriminator was developed As an input and output the AAE uses a vector of binary fingerprints and concentration of t...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2
Sinosh Skariyachan Ph.D. is presently working as Assistant Professor in Microbiology at St. Pius X College, Rajapuram (Aided by Govt. of Kerala, India), Kasaragod, Kerala, India with more than 17 years of experience in teaching and research. One of his key areas of research is computational drug discovery and medicinal chemistry. He has published more than 75 international papers, book chapters, and text books. He is the editor of prestigious journals such as Computers in Biology and Medicine (Elsevier), Frontiers in Microbiology and a referee for more than 125 international journals. He received several awards and grants.
Artificial Intelligence - A current and future tool to learn chemical sciences
Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.
APAC’s Biopharma Providers’ Role in Pioneering a Healthcare Revolution
Narayana is responsible for leading the overall business, P&L, strategy, and program management for Avantor’s Biopharma Business Unit in AMEA. He possesses close to two decades of comprehensive experience in international markets, leading diverse teams in account, product, sales and business management, and delivering strategic solutions for Consumables, systems and Instruments in Academic, Pharmaceuticals, Bioprocessing, and Bioresearch Industries.
Effect of Size of Protein Therapeutics on Brain Pharmacokinetics following Systemic Administration
Chang supports the preclinical-to-clinical PKPD translation and human efficacious dose prediction of new biological entities at Boehringer Ingelheim. Dr. Chang obtained his MS and Ph.D. in Pharmaceutical Sciences at the University at Buffalo. Under Dr. Dhaval Shah’s mentorship, Dr. Chang investigated antibody and protein therapeutic disposition in the rat brain using large-poremicrodialysis and developed a translational brain PBPK model for monoclonal antibodies.
Dhaval K Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the ‘Translational Research-Modeling & Simulation’ group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates.
Shengjia Wu is a PhD student in the pharmaceutical sciences at the State University of New York at Buffalo. His research focuses on understanding and modeling the macromolecule distribution in the central nervous system.
Yingyi Li gained her master’s degree of pharmaceutical sciences in University at Buffalo. When Yingyi was a master student, she was working in Dr. Dhaval Shah’s lab and became more experienced in PBPK modeling. Yingyi is currently a scientist in the field of pharmacometrics and translational PK-PD in Enhanced Pharmacodynamics.
Industry 4.0 at Bachem
Elodie Decuypere received her Ph.D in Organic Synthesis from the University of Paris-Saclay with specialization in Click Chemistry. After her Ph.D, Elodie specialized in oligonucleotide chemistry with her two postdoc in ETH Zürich and Roche Basel. In 2020, Elodie joined Bachem as a Specialist Marketing and works on the creation of scientific content for marketing materials.
press releasesRead more...
Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery
As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company
Collaboration aims to accelerate development of next generation medicines
The Personalised Medicine Centre PMC a joint initiative between Murdoch University and the Perron Institute biotechnology company Syngenis Labs and the Perron Institute are collaborating to establish a specialised preclinical safety testing platform for RNAbased medicines designed to treat diseases...
ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177
ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and AtomVie Global Radiopharma AtomVie a radiopharmaceutical contract development and manufacturing organization CDMO today announced a supply agreement
Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance
Evotec SE NASDAQ EVO Frankfurt Prime Standard EVT today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug IND acceptance from the US Food
Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy
Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy
Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production
Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production
EventsRead more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
03 - 04
Dec 2026Infectious and Rare Diseases
Paris, France
LATEST NEWSRead more...
Bionsight Enters into Collaboration with Astellas to Develop Autoimmune Disorder Therapy
Bionsight has entered into a global research and development RD collaboration with Astellas Pharma to explore a potential firstinclass treatment for autoimmune disorders
Isomorphic Labs Enters into Collaboration with MSD for Cancer Drug Discovery
Isomorphic Labs has entered into a strategic research collaboration with MSD to discover smallmolecule drug candidates for an important oncology target
Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease
Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg
Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments
Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases
OXB Partners with Aura Biosciences for Drug Manufacturing
OXB has confirmed a manufacturing and supply partnership with Aura Biosciences
GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer
GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC


